Skip to main content

MARSHALL WACE, LLP

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1318757 LONDON, X0

Position in REGN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$14,341,420
+$14,068,679 QoQ
Shares Held
23,000
+6415.6% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#246
of 1,322 holders
Holding Since
Jun 2020
24 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in REGN Over Time

Shares Held

Position Value (USD)

Derivatives in REGN

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$79,189,580
PutShares
127,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. REGN ranks #54 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in REGN

Export CSV
31 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $14,341,420 23,000
2026-06-30 $79,189,580 127,000
2026-03-31 $272,741 353
2025-12-31 $77,187 100
2025-12-31 $369,379,159 478,551
2025-09-30 $217,533,266 386,884
2025-09-30 $449,816 800
2025-09-30 $787,178 1,400
2025-06-30 $125,952,225 239,909
2025-03-31 $23,149,395 36,500
2025-03-31 $887,922 1,400
2024-12-31 $90,750,842 127,400
2024-09-30 $140,870,364 134,004
2024-06-30 $61,877,289 58,873
2024-03-31 $192,870,483 200,387
2023-12-31 $83,021,239 94,526
2023-09-30 $86,638,759 105,277
2023-06-30 $103,116,237 143,508
2023-03-31 $74,605,991 90,798
2022-12-31 $6,998,453 9,700
2022-09-30 $2,827,811 4,105
2022-06-30 $30,771,271 52,055
2022-03-31 $2,700,790 3,867
2021-12-31 $81,483,761 129,028
2021-09-30 $62,921,774 103,972
2021-09-30 $8,412,002 13,900
2021-09-30 $1,391,914 2,300
2021-06-30 $40,467,340 72,452
2021-03-31 $8,548,693 18,068
2020-12-31 $1,265,748 2,620
2020-06-30 $8,275,835 13,270